The German company CureVac delivered disappointing preliminary results on Wednesday from a clinical trial of its Covid-19 vaccine, dimming hopes that it could help fill the world’s great need.

The trial, which included 40,000 volunteers in Latin America and Europe, estimated that CureVac’s mRNA vaccine had an efficacy of just 47 percent, among the lowest reported so far from any Covid-19 vaccine maker. The trial will continue as researchers monitor volunteers for new cases of Covid-19, with a final analysis expected in two to three weeks.

“We’re going to full speed for the final readout,” Franz-Werner Haas, CureVac’s chief executive, said in an interview. “We are still planning for filing for approval.”

Continue reading “CureVac’s Covid-19 Vaccine Disappoints in Clinical Trial” →

Novavax, a small American company buoyed by lavish support from the U.S. government, announced on Monday the results of a clinical trial of its Covid-19 vaccine in the United States and Mexico, finding that its two-shot inoculation provides potent protection against the coronavirus.

In the 29,960-person trial, the vaccine demonstrated an overall efficacy of 90.4 percent, on par with the vaccines made by Pfizer-BioNTech and Moderna, and higher than the one-shot vaccine from Johnson & Johnson. The Novavax vaccine showed an efficacy of 100 percent at preventing moderate or severe disease.

Continue reading “Novavax Offers U.S. a Fourth Strong Covid-19 Vaccine” →

Among the thousands of pages of Dr. Anthony S. Fauci’s emails released recently by BuzzFeed News, a short note from Kristian Andersen, a virologist at the Scripps Research Institute in La Jolla, Calif., has garnered a lot of attention.

Over the past year, Dr. Andersen has been one of the most outspoken proponents of the theory that the coronavirus originated from a natural spillover from an animal to humans outside of a lab. But in the email to Dr. Fauci in January 2020, Dr. Andersen hadn’t yet come to that conclusion. He told Dr. Fauci, the government’s top infectious disease expert, that some features of the virus made him wonder whether it had been engineered, and noted that he and his colleagues were planning to investigate further by analyzing the virus’s genome.

Continue reading “Scientist Opens Up About His Early Email to Fauci on Virus Origins” →

Dr. Adam Zeman didn’t give much thought to the mind’s eye until he met someone who didn’t have one. In 2005, the British neurologist saw a patient who said that a minor surgical procedure had taken away his ability to conjure images.

Over the 16 years since that first patient, Dr. Zeman and his colleagues have heard from more than 12,000 people who say they don’t have any such mental camera. The scientists estimate that tens of millions of people share the condition, which they’ve named aphantasia, and millions more experience extraordinarily strong mental imagery, called hyperphantasia.

In their latest research, Dr. Zeman and his colleagues are gathering clues about how these two conditions arise through changes in the wiring of the brain that join the visual centers to other regions. And they’re beginning to explore how some of that circuitry may conjure other senses, such as sound, in the mind. Eventually, that research might even make it possible to strengthen the mind’s eye — or ear — with magnetic pulses.

Continue reading “Many People Have a Vivid ‘Mind’s Eye,’ While Others Have None at All” →

In December, British researchers discovered that a new variantwas sweeping through their country. When it arrived in other countries, the variant, now known as Alpha, tended to become more common in its new homes as well. By April, it had become the dominant variant in the United States, and it has remained so ever since.

Alpha’s swift success has left scientists wondering how the variant conquered the world. A new study points to one secret to its success: Alpha disables the first line of immune defense in our bodies, giving the variant more time to multiply.

Continue reading “How the ‘Alpha’ Coronavirus Variant Became So Powerful” →